Literature DB >> 32200365

Differences of TNF-α, IL-6 and Gal-3 in lobar pneumonia and bronchial pneumonia caused by mycoplasma pneumoniae.

Fang Tian1, Li-Ping Chen1, Gang Yuan2, Ai-Min Zhang1, Yu Jiang1, Shuang Li1.   

Abstract

OBJECTIVE: To investigate the differences of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and galectin-3 concentrations in lobar pneumonia and bronchopneumonia induced by mycoplasma pneumoniae (MP) in children and to explore these related factors predicting the severity of MP.
METHODS: A total of 148 children with mycoplasma pneumoniae pneumonia (MPP) and 32 healthy controls were analyzed from March 2017 to August 2018 in our province. Clinical information was collected from the hospitalized MP patients. The 148 patients with MPP were divided into two groups: lobar pneumonia group and bronchial pneumonia group. The 32 healthy children were considered the control group. The concentrations of TNF-α, IL-6 and Gal-3 were examined in the serum of 148 children patients with MPP and 32 healthy children by double-antibody sandwich enzyme-linked immunosorbent assay (ELISA).
RESULTS: The TNF-α, IL-6 and Gal-3 levels were obviously higher in both the lobar pneumonia and bronchial pneumonia groups, compared to those in the control group. Furthermore, these levels were significantly higher in the lobar pneumonia group, compared to the bronchial pneumonia group. After treatment, the levels of TNF-α, IL-6 and Gal-3 totally descended during the recovery period.
CONCLUSION: There are differences in serum TNF-α, IL-6 and Gal-3 concentrations in lobar pneumonia and bronchial pneumonia caused by MP in children. In general, the TNF-α, IL-6 and Gal-3 levels were significantly higher in the lobar pneumonia group, when compared to the bronchial pneumonia group. This was because most lobar pneumonia cases are much more serious than bronchial pneumonia. Moreover, it has been proven that TNF-α, IL-6 and Gal-3 may play an important role in the pathogenesis development of MPP. At the same time, these are important issues in diagnosing MPP.

Entities:  

Keywords:  Gal-3; IL-6; Mycoplasma pneumonia; TNF-α; bronchial pneumonia; galctin-3; interleukin-6; lobar pneumonia; tumor necrosis facto-alpha

Year:  2020        PMID: 32200365     DOI: 10.3233/THC-192011

Source DB:  PubMed          Journal:  Technol Health Care        ISSN: 0928-7329            Impact factor:   1.285


  7 in total

1.  Blockade of interleukin-6 receptor attenuates apoptosis and modulates the inflammatory response in Mycoplasma pneumoniae infected A549 cells.

Authors:  Wei Fang; Jingyu Huang; Jun Wang; Tengyi Huang; Dajia Lin; Jun Yin
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

2.  The Diagnostic Value of High-Resolution Computed Tomography Features Combined with Mycoplasma Pneumoniae Ribonucleic Acid Load Detection for Refractory Mycoplasma Pneumonia.

Authors:  Hongping Wei; Chunyan Wang; Lili Ding; Min Wu
Journal:  Contrast Media Mol Imaging       Date:  2022-05-04       Impact factor: 3.009

3.  The Therapeutic Potential of Galectin-3 in the Treatment of Intrahepatic Cholangiocarcinoma Patients and Those Compromised With COVID-19.

Authors:  Hao Li; Jianmin Li; Wei Xiao; Yujing Zhang; Yuan Lv; Xing Yu; Jiao Zheng
Journal:  Front Mol Biosci       Date:  2021-05-24

4.  Study on the Therapeutic Effect of Azithromycin Combined with Glucocorticoid on Pulmonary Function and Inflammatory Response in Children with Pneumonia.

Authors:  Qingchun Zhao; Junbo Yang; Yongmei Sheng; Min Zhuang; Min Qi
Journal:  J Healthc Eng       Date:  2022-03-27       Impact factor: 2.682

5.  Radiological patterns and prognosis in elderly patients with acute Klebsiella pneumoniae pneumonia: A retrospective study.

Authors:  Kosaku Komiya; Hiroki Yoshikawa; Akihiko Goto; Takashi Yamamoto; Mari Yamasue; Takeshi Johkoh; Kazufumi Hiramatsu; Jun-Ichi Kadota
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

Review 6.  Cellular and Molecular Mechanism of Pulmonary Fibrosis Post-COVID-19: Focus on Galectin-1, -3, -8, -9.

Authors:  Daniela Oatis; Erika Simon-Repolski; Cornel Balta; Alin Mihu; Gorizio Pieretti; Roberto Alfano; Luisa Peluso; Maria Consiglia Trotta; Michele D'Amico; Anca Hermenean
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

7.  Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider.

Authors:  Juan Garcia-Revilla; Tomas Deierborg; Jose Luis Venero; Antonio Boza-Serrano
Journal:  Front Immunol       Date:  2020-08-18       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.